Revvity drops nearly 8% as investors de-risk ahead of May 5 earnings
Revvity shares slid as investors positioned ahead of the company’s next catalyst: first-quarter 2026 results due before the open on May 5, 2026, with a 7:30 a.m. ET conference call. The decline also comes amid recent analyst price-target cuts and neutral stances that have pressured sentiment into earnings.
1) What’s moving the stock today
Revvity (RVTY) is down about 7.9% in Thursday trading (April 23, 2026) as the stock sees pre-earnings de-risking ahead of its first-quarter 2026 results, scheduled for release before market open on May 5, 2026, followed by a 7:30 a.m. ET conference call. The timing puts the company’s next update less than two weeks away, and traders are resetting exposure after recent volatility in life-science tools/diagnostics names. (news.revvity.com)
2) Why sentiment is fragile into the print
Revvity entered 2026 with guidance calling for total revenue of $2.96–$2.99 billion, organic revenue growth of 2–3%, and adjusted EPS of $5.35–$5.45—numbers that frame a moderate-growth profile and can amplify downside sensitivity if investors worry about execution or end-market demand. In recent weeks, multiple firms have cut price targets and shifted to more cautious ratings, reinforcing a “wait-and-see” setup into the next earnings release. (news.revvity.com)
3) What to watch next
The key near-term swing factor is whether Revvity can deliver Q1 results that support its 2026 outlook, especially around growth in Life Sciences and profitability trends in Diagnostics. Any commentary on order trends and demand durability will likely matter as much as headline EPS, given the stock’s recent sensitivity to guidance and margin trajectory.